Weight-Loss combo CagriSema tested for drug interactions

NCT ID NCT06289504

Completed Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study in 34 adults with overweight or obesity examined whether CagriSema (a combination of cagrilintide and semaglutide) changes how the body processes atorvastatin (a cholesterol drug) and warfarin (a blood thinner). Participants took single doses of atorvastatin and warfarin before and after reaching steady-state levels of CagriSema. The goal was to measure drug levels in the blood and the effect of warfarin, helping guide safe co-prescribing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CagriSema (cagrilintide and semaglutide combination)
What this could lead to: If successful, this study could help doctors understand how to safely prescribe common medications like atorvastatin and warfarin alongside CagriSema for weight management.
What could go wrong: This is a small, early-stage drug interaction study, not a test of weight loss or safety. Results may not apply to broader populations or predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Altasciences Company Inc.

Montreal, Quebec, H3P 3P1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.